Hua Lee Yu

7951374, May 31, 2011

Dec 14, 2005

11/300619

Hua E. Yu - Glendora CA, US
Richard Jove - Glendora CA, US
Marcin Kortylewski - Rancho Cuamonga CA, US
Drew M. Pardoll - Brookeville MD, US

University of South Florida - Tampa FL
The Johns Hopkins University - Baltimore MD

A61K 39/00

4241781, 4241301

Methods of enhancing antitumor activity of an immune cell comprising contacting the immune cell with a Stat3 inhibitor are described. Also described are methods of killing a tumor cell or inhibiting tumor growth in a subject comprising contacting an immune cell of the subject with a Stat3 inhibitor.

20060030536, Feb 9, 2006

Apr 8, 2005

11/102911

Hua Yu - Glendora CA, US
Richard Jove - Glendora CA, US
Jin Cheng - Tampa FL, US
Guilian Niu - Zephryhills FL, US
Said Sebti - Tampa FL, US

University of South Florida - Tampa FL

A61K 48/00
A61K 39/395

514044000, 424155100

Compositions and methods for treating cancer and proliferative angiopathies are provided. A composition can include an inhibitor of the Jak2/Stat3 signaling pathway and an inhibitor of the PI3k/Akt signaling pathway. In certain cases, the two inhibitors are capable of acting synergistically as compared to either inhibitor alone.

20080214436, Sep 4, 2008

Dec 28, 2007

11/966423

Hua YU - Glendora CA, US
Marcin KORTYLEWSKI - Monrovia CA, US
Richard JOVE - Glendora CA, US
Piotr Marek SWIDERSKI - San Dimas CA, US
John J. ROSSI - Alta Loma CA, US

CITY OF HOPE - Duarte CA

A61K 38/00
C07H 21/00
C07K 1/00
A61P 43/00
A61K 31/70

514 2, 536 245, 536 231, 530300, 514 44

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.

20110071210, Mar 24, 2011

Sep 10, 2010

12/879199

Hua YU - Glendora CA, US
Marcin KORTYLEWSKI - Monrovia CA, US
Richard JOVE - Glendora CA, US
Piotr Marek SWIDERSKI - San Dimas CA, US
John J. ROSSI - Alta Loma CA, US

CITY OF HOPE - DUARTE CA

A61K 48/00
C07H 21/04
C07H 21/02
A61P 31/00
A61P 37/06
A61P 35/00

514 44 A, 536 241, 514 44 R

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.

20120065125, Mar 15, 2012

Sep 9, 2011

13/229146

Hua YU - Glendora CA, US
Marcin KORTYLEWSKI - Monrovia CA, US
Richard JOVE - Glendora CA, US
Piotr Marek SWIDERSKI - San Dimas CA, US
John J. ROSSI - Alta Loma CA, US

CITY OF HOPE - Duarte CA

A61K 31/713
A61K 31/7105
A61P 37/00
A61P 31/00
A61P 7/00
A61K 38/02
C07H 21/02
A61P 35/00

514 23, 536 245, 514 44 A, 514 44 R, 514 193, 514 133, 536 235

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.

20130052731, Feb 28, 2013

Mar 19, 2012

13/424267

David Home - Duarte CA, US
Hua Yu - Duarte CA, US

C07K 1/113
C12N 5/09
C07K 1/107

435375, 530358

According to some embodiments, methods for covalently or non-covalently conjugating an antibody (e.g., hu3S193 or other humanized antibody) or functional fragment thereof with an siRNA molecule (e.g., anti-STAT3 siRNA) is provided. Such methods may include (1) modifying an antibody or functional fragment thereof with a linker to provide a linker-modified antibody, combining a target siRNA with a disulfide containing aldehyde linker to provide a linker-modified target siRNA and combining the linker-modified target siRNA with linker-modified antibody to form an antibody-siRNA complex; or (2) modifying an antibody or functional fragment thereof with a (Arginine)peptide to form an antibody-9R complex and associating an siRNA molecule with the antibody-9R complex to form an electrostatic antibody-9R:siRNA complex. In another embodiment, an antibody-siRNA conjugate may be used in methods for suppressing or silencing STAT3 protein expression in a cancer cell.

20210386860, Dec 16, 2021

Mar 30, 2021

17/217989

- Duarte CA, US
Hua Yu - Glendora CA, US

City of Hope - Duarte CA

A61K 47/54
C12N 15/113
A61K 48/00

Provided herein are, inter alia, nucleic acid conjugates including a non-cell penetrating ribonucleic acid compound attached at its 3′ end to a phosphorothioate polymer. Attachment of the phosphorothioate polymer to the non-cell penetrating ribonucleic acid conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating ribonucleic acid. The nucleic acid conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer, inflammatory disease, and pain.

20210330804, Oct 28, 2021

Feb 24, 2021

17/184237

- Duarte CA, US
Hua YU - Glendora CA, US
Piotr Marek SWIDERSKI - San Dimas CA, US
John Ernest SHIVELY - Arcadia CA, US
Lin LI - Monrovia CA, US

A61K 47/68
C07K 16/08
C07K 16/18
C07K 16/40
A61K 47/54
A61K 39/44

Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.